| Size | Price | Stock | Qty |
|---|---|---|---|
| 5g |
|
||
| Other Sizes |
| Targets |
Ethyl oleate does not have a specific pharmacological target, as it is an excipient rather than an active pharmaceutical ingredient. It serves as a solubilizing agent and vehicle for lipophilic drug substances, including steroids and other poorly water-soluble compounds.
|
|---|---|
| ln Vitro |
In vitro, Ethyl oleate is used as a solvent and carrier in pharmaceutical preparations. It is commonly employed to prepare the oily phase of self-microemulsifying drug delivery systems (SMEDDS) for lipophilic drugs such as tacrolimus. It facilitates the solubilization and delivery of poorly water-soluble compounds.
|
| ln Vivo |
In vivo activity data for Ethyl oleate are not applicable, as it is an excipient rather than a pharmacologically active compound. It is used as a vehicle for drug formulations, particularly for injectable preparations and oral suspensions. Its role is to enhance drug solubility and bioavailability.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays are not applicable for Ethyl oleate, as it is an excipient and not a pharmacologically active agent targeting enzymes or receptors. Its function is limited to solubilization and formulation of active pharmaceutical ingredients.
|
| Cell Assay |
Cellular assays for Ethyl oleate are not typically performed, as it is an excipient. When used in drug formulations, its effects on cell viability and permeability may be assessed to evaluate formulation safety and performance. Standard cytotoxicity assays using relevant cell lines may be conducted for formulation development.
|
| Animal Protocol |
In vivo animal protocols for Ethyl oleate are not applicable as a standalone compound. It is used as a formulation vehicle in pharmacokinetic and toxicology studies of drug substances. Standard protocols involve administration of drug formulations containing Ethyl oleate via oral, intravenous, or other routes, with appropriate vehicle control groups.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Ethyl oleate are not characterized as a drug substance. As an excipient, it is metabolized by esterases to oleic acid and ethanol, which are then incorporated into normal metabolic pathways. Its presence in formulations may affect the absorption and bioavailability of co-administered drugs.
|
| Toxicity/Toxicokinetics |
Toxicological data for Ethyl oleate indicate that it is generally recognized as safe for use in pharmaceutical and cosmetic applications. It is considered non-toxic at concentrations used in formulations. Standard safety assessments have been conducted for its use as a food additive and pharmaceutical excipient.
|
| References | |
| Additional Infomation |
Ethyl oleate is a long-chain fatty acid ethyl ester formed by the condensation of the carboxyl group of oleic acid and the hydroxyl group of ethanol. It is a plant metabolite and acaricide, functionally related to oleic acid. Ethyl oleate has been reported in Aristolochia fontanesii, Mitracarpus hirtus, and other organisms with relevant data.
Ethyl oleate is a widely used pharmaceutical excipient, solvent, and solubilizing agent. It is used in the preparation of injectable formulations, oral suspensions, and self-microemulsifying drug delivery systems (SMEDDS). It is also used as a lubricant and plasticizer. The compound is for research and pharmaceutical use and is not an active therapeutic agent. |
| Molecular Formula |
C20H38O2
|
|---|---|
| Molecular Weight |
310.5145
|
| Exact Mass |
310.287
|
| CAS # |
111-62-6
|
| PubChem CID |
5363269
|
| Appearance |
Colorless to light yellow liquid
|
| Density |
0.87 g/mL at 25 °C(lit.)
|
| Boiling Point |
216-218 °C15 mm Hg
|
| Melting Point |
−32 °C(lit.)
|
| Flash Point |
91.8±20.4 °C
|
| Vapour Pressure |
0.0±0.9 mmHg at 25°C
|
| Index of Refraction |
1.455
|
| LogP |
8.69
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
17
|
| Heavy Atom Count |
22
|
| Complexity |
258
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O(C([H])([H])C([H])([H])[H])C(C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C(/[H])=C(/[H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H])=O
|
| InChi Key |
LVGKNOAMLMIIKO-QXMHVHEDSA-N
|
| InChi Code |
InChI=1S/C20H38O2/c1-3-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20(21)22-4-2/h11-12H,3-10,13-19H2,1-2H3/b12-11-
|
| Chemical Name |
ethyl (Z)-octadec-9-enoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~50 mg/mL (~161.03 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (8.05 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.5 mg/mL (8.05 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (8.05 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.2205 mL | 16.1025 mL | 32.2051 mL | |
| 5 mM | 0.6441 mL | 3.2205 mL | 6.4410 mL | |
| 10 mM | 0.3221 mL | 1.6103 mL | 3.2205 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
